January 13, 2021 11:14 AM ESTUpdated 02:03 PM
Financing

Pfiz­er's in­vest­ment fund is mak­ing waves in VC — in­clud­ing a $25M bet on IBD play­er Vedan­ta Bio­sciences

Nicole DeFeudis

Editor

Pfiz­er has a gut feel­ing about Vedan­ta Bio­sciences.

On Tues­day, the Cam­bridge, Mass­a­chu­setts-based mi­cro­bio­me up­start be­came the fourth biotech to re­ceive an in­vest­ment from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times